SPDR® S&P International HealthC Sect ETF

Most Recent

  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Valuation Cheat Sheet

    On January 26, 2017, the company was trading at a forward PE of ~15.8x. Based on the last five years’ multiple range, JNJ’s current valuation is neither high nor low.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why the Majority of Analysts Deem Novartis a ‘Buy’

    Novartis met Wall Street analysts’ estimates for EPS (earnings per share) in 4Q16, reporting EPS of $1.12 as estimated but missing revenue estimates.

    By Mike Benson
  • uploads///Chart  KPP
    Company & Industry Overviews

    Quarterly Performance of GlaxoSmithKline’s Global Pharmaceuticals

    GlaxoSmithKline’s (GSK) immuno-inflammation franchise, which includes Benlysta, reported a rise of 9.0% in revenues at constant exchange rates to 93.0 million pounds in 2Q17 compared to 2Q16.

    By Mike Benson
  • uploads///Chart  Val
    Miscellaneous

    Novartis’s Valuation after 1Q17 Earnings

    On April 27, 2017, Novartis was trading at a forward PE multiple of ~15.8x. The industry currently trades at a forward PE multiple of ~15.9x.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Performance of GlaxoSmithKline’s HIV Business in 2016

    HIV products reported growth of 37% to ~3.6 million pounds in 2016 compared to 2015.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How GlaxoSmithKline’s Valuation Compares to Its Peers’

    According to data released on December 28, 2016, GlaxoSmithKline’s stock has fallen ~5.1% over the last 12 months. What do analysts expect for the next 12 months?

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Roche’s Oncology Wheelhouse Stacked with Competitive Drugs

    Headquartered in Basel, Switzerland, Roche (RHHBY) is a leading pharmaceutical company. Roche’s Pharmaceuticals and Diagnostics businesses comprise more than 77% and ~22.5%, respectively, of the company’s total revenues.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.